Germany’s Federal Ministry of Health (BMG) initiated two research funding projects to strengthen women's health | iPharmaCenter

J.P. Morgan 2026 Healthcare Conference | News | Updates | iPharmaCenter

Inside Trump’s Great Healthcare Plan: Drug Prices, Premiums, and Transparency Explained

Sun Pharma Launches UNLOXCYT in the U.S. for Advanced Cutaneous Squamous Cell Carcinoma

American Society of Clinical Oncology Gastrointestinal (ASCO GI) Cancers Symposium 2026 | News | Updates | iPharmaCenter

Top-Selling Drugs of 2026 | iPharmaCenter

Germany Approves Draft Law to Strengthen Local Pharmacies (ApoVWG) | iPharmaCenter

Eli Lilly to acquire Ventyx Biosciences; will significantly strengthen immunology and neurology portfolio | iPharmaCenter

China Grants Approval to Nucala for COPD Management | iPharmaCenter

Japan approves GSK's Exdensur for asthma and chronic rhinosinusitis with nasal polyps

Enhertu approved in China for HER2‑low or HER2‑ultralow metastatic breast cancer | iPharmaCenter

European Commission grants approval to Sanofi's Wayrilz for refractory immune thrombocytopenia | iPharmaCenter

Boehringer Ingelheim Bolsters Pulmonary Fibrosis Portfolio with Jascayd Approval for Progressive Cases

FDA Clears Wegovy Pill as First Oral GLP-1 for US Weight Management

US FDA Grants Approval to Exdensur, ultra-long acting biologic for Severe Eosinophilic Asthma

GSK, Novartis, Merck, Gilead, BMS and Amgen cut US drug prices for tariff relief and massive US investment

American Society of Hematology (ASH) Annual Meeting and Exposition | ASH 2025 | Orlando, Florida | iPharmaCenter

HAS Provides Conditional Reimbursement for Pirtobrutinib and Restricted Use for Upadacitinib | iPharmaCenter

PBS Adds Zytorvi, First Funded Immunotherapy Option for Australians with Recurrent or Metastatic Nasopharyngeal Carcinoma | iPharmaCenter

FDA Clears Breyanzi as the First CAR T‑Cell Therapy for Relapsed or Refractory Marginal Zone Lymphoma in the US | iPharmaCenter

Johnson & Johnson Secures European Commission Approval for IMAAVY (Nipocalimab) to Treat Generalised Myasthenia Gravis

Sun Pharma Launches ILUMYA in India for Psoriasis Patients | iPharmaCenter

US FDA Accepts AstraZeneca’s Baxdrostat for Priority Review in Resistant Hypertension

FDA Approves Jaypirca for Relapsed or Refractory CLL/SLL Previously Treated with Covalent BTK Inhibitors | iPharmaCenter

Best‑Selling Cancer Drugs 2025: Top 10 Brands, Uses and MOA | Best selling cancer drugs | 2025 | iPharmaCenter

Top 10 pharmaceutical companies by revenues | 2025 | iPharmaCenter

CTAD 2025: Eisai Highlights Etalanetug Tau Reductions and LEQEMBI Protofibril Data; Merck Shares Early MK-2214, MK-1167 Results | Clinical Trials on Alzheimer's Disease 2025 | iPharmaCenter

Bristol Myers Squibb Extends Cobenfy Trial in Alzheimer’s Psychosis After DMC Recommendation | iPharmaCenter

Dual Special Needs Plans (D-SNPs) and Key 2026 Changes: What Dual Eligibles Need to Know During Medicare Enrollment | iPharmaCenter

Eli Lilly Cuts Zepbound Prices on Single‑Dose Vials to Expand Obesity Drug Access in the US | iPharmaCenter

US–Swiss Tariff Cap Impact on Pharma: How the New US–Swiss Tariff Cap Shapes Pharma and Health Security

NICE’s New £35k/QALY Era: Ripple Effects for Australia’s PBS and Other HTA Markets | NICE Cost Effectiveness Threshold | iPharmaCenter

NICE increased cost effectiveness threshold from £20,000-£30,000/QALY to £25,000-£35,000/QALY

CMS Launches ACCESS Outcome-Aligned Payment Model for High-Burden Chronic Conditions | iPharmaCenter

FDA Clears Imfinzi as First Perioperative Immunotherapy for Resectable Gastric and GEJ Cancers | iPharmaCenter

EU clears Dupixent as first targeted CSU therapy in over a decade | iPharmaCenter

FDA Greenlights Kygevvi as Pioneering Therapy for Thymidine Kinase 2 Deficiency in Adults and Kids | iPharmaCenter

China NMPA Approves Pfizer’s Matazisimab (You Ruiting) for Routine Prophylaxis in Hemophilia Patients with Inhibitors | iPharmaCenter

CMS Projects Billions in Future Savings for Seniors; Maximum Fair Price (MFP) Negotiation Policy Originated Under Biden Administration | iPharmaCenter

CMS Introduces Proposed Rule to Elevate Quality and Access in Medicare Advantage and Part D | iPharmaCenter

NICE Approves Autolus’ Obe-cel CAR-T Therapy for Adults with Rare Blood Cancer | iPharmaCenter

BMS' Breyanzi CAR-T Therapy Approved for Treating Mantle Cell Lymphoma | iPharmaCenter

Novartis Receives FDA Approval for Itvisma, Expanding Access to Gene Replacement Therapy for People of All Ages Living with Spinal Muscular Atrophy (SMA)

The Pharma Top 10: Highest Revenue Drugs of 2025 (Official Sales Data & Analysis) | Top selling pharmaceutical drugs | iPharmaCenter

Germany Signals Major Health System Overhaul as Minister Warken Warns of Growing Deficits | iPharmaCenter

FDA Approves KEYTRUDA and KEYTRUDA QLEX in Combination with Padcev as Perioperative Treatment for Cisplatin-Ineligible Muscle-Invasive Bladder Cancer | iPharmaCenter

Novartis hopes its cancer drugs drive revenues until 2030 | iPharmaCenter

Roche’s Giredestrant Leads the Way as First Oral SERD to Improve Outcomes in Early Breast Cancer | iPharmaCenter

FDA Approves Epkinly in Combination with Rituximab and Lenalidomide for Relapsed or Refractory Follicular Lymphoma | iPharmaCenter

American College of Rheumatology (ACR) Convergence | Chicago | 2025 | iPharmaCenter